Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司2021年限制性股票激励计划首次授予事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2021 restricted stock incentive plan initial grant. It discusses legal compliance, approvals, authorizations, and conditions related to the stock incentive plan. It is not a financial report, earnings release, or regulatory filing per se, but a legal opinion supporting a capital incentive plan. This type of document is best classified under Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update or Remuneration Information, and it is not a report or announcement of voting results. The document length is over 6,000 characters and contains substantive legal content, not just an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-01-28 Chinese
金陵药业2021年限制性股票激励计划首次授予部分激励对象名单（截至授予日)
Remuneration Information Classification · 95% confidence The document is a detailed list of recipients of a 2021 restricted stock incentive plan, including names, positions, and stock quantities. It focuses on the allocation of stock incentives to management and core personnel. This type of document is related to executive compensation and stock incentive plans, which falls under remuneration information. It is not a full annual report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement. The document is not a regulatory filing or announcement of a report but a substantive disclosure of remuneration-related stock incentives. Therefore, the best fitting category is Remuneration Information (DEF 14A). The document length (4433 characters) is sufficient to contain detailed information rather than a brief announcement.
2022-01-28 Chinese
金陵药业独立董事关于公司第八届董事会第十七次会议审议的有关议案及相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the company's board meeting resolutions, specifically about the initial grant of restricted shares under an incentive plan. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content focuses on governance and approval of share-based incentives rather than financial results or audit findings. The document length is short (943 characters) and it is a formal opinion related to board decisions, not a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2022-01-28 Chinese
金陵药业股份有限公司关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant of restricted shares under a stock incentive plan by Jinling Pharmaceutical Co., Ltd. It details the grant date, number of shares, price, recipients, conditions, and approvals related to the stock incentive plan. It includes legal and financial advisor opinions, but it is not a financial report or earnings release. It is a formal announcement about a capital/financing event related to share issuance to incentivize employees and management. Therefore, it fits best under Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing. Confidence is high due to the specificity and content of the announcement.
2022-01-28 Chinese
金陵药业股份有限公司2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and voting process. The content focuses on the official results of shareholder votes on multiple agenda items, including board member appointments, amendments to company articles, stock incentive plans, and related party transactions. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a proxy solicitation or a presentation but an official declaration of voting results from a shareholders' meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4324 characters, which is sufficient to contain detailed voting results rather than a brief announcement or a report publication notice.
2022-01-27 Chinese
金陵药业股份有限公司关于公司2021年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Director's Dealing Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to a 2021 restricted stock incentive plan by Jinling Pharmaceutical Co., Ltd. It details the investigation of stock transactions by insiders and incentive recipients during a specified period, ensuring compliance with regulatory requirements. The document includes specific transaction data and concludes no insider trading occurred. It is a regulatory announcement about insider dealings and compliance, not a financial report, earnings release, or management report. It fits best under Director's Dealing (DIRS) as it reports on insider stock transactions and compliance with insider information regulations.
2022-01-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.